Trial Updates

Lecanemab: a review

Lecanemab: drawbacks to consider

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

New pivotal study using photobiomodulation in Alzheimer’s treatment

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

First-in-human clinical trial of the anti-PD-L1 antibody, IBC-Ab002, in early AD

Speech biomarker for cognition: a novel marker for AD clinical trial screening

Lecanemab and what this means for the future treatment of Alzheimer’s disease

Is amyloid load a valid surrogate endpoint for AD clinical trials?

The future of SAGE-718 in Alzheimer’s disease treatment

The Phase III NILEAD trial: nilotinib as a novel treatment for AD

Challenges in designing clinical trials for dementia with Lewy bodies

Insights into the upcoming LIGHTWAVE trial using SAGE-718 to treat patients with MCI and early AD

The COCOA Trial: can multimodal lifestyle interventions treat AD?

Long-term transdermal nicotine for the treatment of mild cognitive impairment

The PreventE4 study: testing omega-3 supplementation in APOE4 carriers before the onset of dementia